NCT04001621进行中（未招募）2 期
Phase II Study of Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
Trastuzumab resistance, which is a common therapeutic challenge in HER2 positive metastatic breast cancer, is not fully understood. Pyrotinib is an oral tyrosine kinase inhibitor targeting EGFR, HER-2 and HER-4 receptors. More general inhibition of ErbB family with pyrotinib could provide additional benefit. This study is designed to evaluate the efficacy and safety of pyrotinib in combination with capecitabine in patients with HER2 positive locally advanced or metastatic breast cancer who had early failure on or after trastuzumab treatment.
详细描述
A multi-center, one-arm, open label design study, which is planned to enroll 100 patients with trastuzumab-resistant HER2-positive advanced breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed HER2 positive patients with locally advanced or metastatic breast cancer: HER2 IHC 3+, or HER2 IHC 2+ and FISH detection gene amplification
- •Aged ≥18 and ≤70 years.
- •ECOG performance status of 0 to
- •Life expectancy of more than 12 weeks;
- •At least one measurable lesion exists(RECIST 1.1)
- •Patients with trastuzumab resistance is defined as follows:
- •Progression during or within 12 months after treatment in neoadjuvant or adjuvant setting (at least 9 weeks of trastuzumab treatment); Or Progression during or within 6 months after treatment for locally advanced or metastatic disease in the first-line setting (at least 6 weeks of trastuzumab treatment).
- •At least 4 weeks from the last treatment of trastuzumab or chemotherapy，at least 5 times of t1/2 or 4 weeks from the last treatment of endocrine therapy（the shorter one is preferred）
- •Known hormone receptor status
- •For patients with brain metastases, local treatment (including whole cranial radiotherapy, SBRT, etc.) is required and the brain lesions are stable for ≥ 3 months without the need for dexamethasone or mannitol treatment
- •Patients with adequate organ function before enrollment:
- •ANC≥1.5×10^9/L
- •PLT≥100×10^9/L
- •TBIL≤1.5×ULN
- •ALT and AST≤3×ULN, （ALT and AST≤5×ULN in patients with liver metastases）
- •Cr≤1.5×ULN and the creatinine clearance rate≥50 mL/min
- •QTcF < 480 ms
- •Signed informed consent.
排除标准
- •Patients with meningeal metastasis and / or spinal cord metastasis;
- •Patients unable to swallow, with chronic diarrhea, intestinal obstruction, or multiple factors that affect drug use and absorption;
- •Patients with malignant serious effusion which cannot be controlled by drainage or other methods;
- •Less than 4 weeks from the last treatment in last clinical trial;
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency;
- •Receiving any other antitumor therapy;
- •History of other malignancy within the last 5 years, except for carcinoma in situ of cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent;
- •Received radiotherapy, surgery (excluding local puncture) within 4 weeks prior to enrollment; received anti-tumor endocrine therapy after entering the screening period;
- •Previous or ongoing use of HER2-targeted tyrosine kinase inhibitors (lapatinib, neratinib or pyrotinib);
- •Previous use of capecitabine or capecitabine not tolerated, except that capecitabine efficacy cannot be judged or capecitabine discontinuation for 3 months or more;
- •Patients with serious heart disease;
- •Allergy to pyrotinib; history of immunodeficiency, including HIV positive, active HBV/HCV or other acquired, congenital immunodeficiency disease, or organ transplantation history;
- •Known history of neurological or psychiatric disease, including epilepsy or dementia;
- •Patients during pregnancy or lactation, patients with childbearing potential tested positive in baseline pregnancy test, or patients unwilling to take effective contraceptive measures throughout the trial;
- •Evidence of significant medical illness that will substantially increase the risk on the participation or completion of the study in the investigator's judgment. Examples included, but not limited to, hypertension, severe diabetes, etc;
- •Patients not eligible for this study judged by the investigator.
研究组 & 干预措施
Pyrotinib plus capecitabine
Experimental
pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
干预措施: Pyrotinib combined with capecitabine (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: Estimated 12 months
From enrollment to progression or death (for any reason)
次要结局
- Objective Response Rate (ORR)(Estimated 12 months)
- Duration of Response (DOR)(Estimated 12 months)
- Clinical Benefit rate (CBR)(Estimated 12 months)
- Overall Survival (OS)(Estimated 24 months)
- Adverse Events and Serious Adverse Events(From informed consent through 28 days following treatment completion)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast CancerMetastatic Breast CancerNCT04963595Zhiyong Yu100
Unknown
2 期
Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerHER2 Gene MutationBreast CancerNCT03412383Peking Union Medical College14
招募中
3 期
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and TrastuzumabHER2-positive Breast CancerMetastatic Breast CancerNCT05346861Fudan University240
尚未招募
不适用
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyHER2+ Advanced Breast Cancer Patients Progressing on TKI TherapyNCT05560308Tianjin Medical University Cancer Institute and Hospital50
Unknown
2 期
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast CancerMetastatic Breast CancerNCT04034589Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University46